MedTrace Logo

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

NCT03123484 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-04-21

No results posted yet for this study

Summary

Epidermal Growth Factor Receptor tyrosine-kinase inhibitors （EGFR-TKIs）, including gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

β-elemene

β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days

DRUG

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • General Hospital of Shenyang Military Region

    collaborator OTHER

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Liu yunpeng, PhD · Director of Department of Medical Oncology,The First Hospital of China Medical University Affiliation: China Medical University, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-30
Primary Completion
2019-04-30
Completion
2019-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03123484 on ClinicalTrials.gov